Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Patent
1998-04-27
2000-10-03
Ford, John M.
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
544 60, 544115, 540575, C07D48702
Patent
active
061275417
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to imidazoquinazoline derivatives or pharmaceutically acceptable salts thereof which have the cyclic guanosine 3',5'-monophosphate (cGNP)--specific phosphodiesterase (PDE)inhibitory activity and are useful for treating or ameliorating cardiovascular diseases such as thrombosis, angina pectoris, hypertension, heart failure, arterial sclerosis, as well as asthma, impotence and the like.
BACKGROUND OF THE INVENTION
cGMP plays an important role as a second messenger in intracellular signal transduction. An inhibitor of cGMP-specific PDE, an enzyme which degrades cGMP, increases the concentration of intracellular cGMP, enhances the effects of endothelium-derived relaxing factor (EDRF), nitro vasodilator or atrial natriuretic peptide, shows the anti-platelet activity, the anti-vasocontraction activity and the vasodilating activity, and are useful for treating cardiovascular diseases such as thrombosis, angina pectoris, hypertension, congestive heart failure, post-PTCA restenosis, peripheral vascular diseases, arterial sclerosis etc., inflammatory allergic diseases such as bronchitis, chronic asthma, allergic asthma, allergic coryza etc., alimentary canal diseases such as irritable intestine syndrome etc., glaucoma, impotence and the like. The PDE inhibitory activity and the adenosine receptor antagonistic activity of imidazo[4,5-g]quinazoline derivatives are described in J. Med. Chem., 29, 972 (1986), J. Med. Chem., 32, 2247 (1989), J. Org. Chem., 51, 616 (1986) and the references cited therein. However, these compounds are neither particularly strong PDE inhibitors nor selective cGMP-specific PDE inhibitors.
Further, 8-anilino-2,3-dihydro-1H-imidazo[4,5-g]quinazoline-2-one derivatives are disclosed in EP635507. However, a substituent at 8-position in the compounds described in EP635507 is limited to an anilino group. Further, there is no description in EP635507 of the PDE inhibitory activity of the compounds.
In addition, 2,3-dihydro-1H-imidazo[4,5-g]quinazoline derivatives with cCMP-specific PDE inhibitory activity are disclosed in WO95/06648. However, in the case where a substituent at the 8-position in the compounds in WO95/06648 is aralkyl, a substituent in the aryl moiety of said aralkyl is limited to dialkyl-substituted amino such as dimethyl amino etc., lower alkyl, lower alkoxy, halogen and trifluoromethyl. There is no description therein of those compounds where the substituent in the aryl moiety of the aralkyl is monoalkyl-substituted amino or those compounds having cyclic amino groups such as morpholino, piperidino and thiomorpholino.
The PDE inhibitors known so far inhibit not only cGMP-specific PDE but also the cyclic adenosine 3',5'-monophosphate (cAMP) specific PDE which is an enzyme similar thereto, and therefore causes the elevation of the concentration of cAMP as well as intracellular cGMP and may cause side effects and the like. Further, the inhibitory activities thereof are not yet sufficient, and compounds which are more potent and selective are expected and desired.
DISCLOSURE OF THE INVENTION
The object of the invention is to provide imidazoquinazoline derivatives or pharmaceutically acceptable salts thereof which have potent and selective cGMP-specific PDE inhibitory activity, increases the concentration of intracellular cGMP, enhances the effects of endothelium-derived relaxing factor (EDRF), nitro vasodilator or atrial natriuretic peptide, shows the anti-platelet activity, the anti-vasocontraction activity and the vasodilating activity, and are useful for treating or ameliorating cardiovascular diseases such as thrombosis, angina pectoris, hypertension, congestive heart failure, post-PTCA restenosis, peripheral vascular diseases, arterial sclerosis etc., inflammatory allergic diseases such as bronchitis, chronic asthma, allergic asthma, allergic coryza etc., alimentary canal diseases such as irritable intestine syndrome etc., glaucoma, impotence and the like.
The present invention relates to imidazoquinazoline derivatives repr
REFERENCES:
patent: 5661147 (1997-08-01), Machii et al.
patent: 5679683 (1997-10-01), Bridges et al.
J. Org. Chem., vol. 51, No. 5 (1986) 616-620.
J. Med. Chem., vol. 29, No. 6 (1986) 972-978.
J. Med. Chem., vol. 32, No. 10 (1989) 2247-2254.
Ichimura Michio
Nomoto Yuji
Ohno Tetsuji
Onoda Yasuo
Yamada Koji
Ford John M.
Kyowa Hakko Kogyo Co. Ltd.
LandOfFree
Imidazoquinazoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazoquinazoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazoquinazoline derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-197235